Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair
Oncology Reports · 2024
DOI: 10.3892/or.2024.8749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2024. Verfasst von Naoko Ida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910‑1193, Japan. Hauptthemen laut MEDLINE: Phthalazines, Poly(ADP-ribose) Polymerase Inhibitors, Piperazines, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University of Fukui, Matsuoka, Eiheiji, Fukui 910‑1193, Japan.
- Department of Blood Transfusion, University of Fukui Hospital, Matsuoka, Eiheiji, Fukui 910‑1193, Japan.
Zitieren
APA
Ida, N., Okura, M., Tanaka, S., Hosono, N., & Yamauchi, T. (2024). Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair. Oncology Reports. https://doi.org/10.3892/or.2024.8749
Vancouver
Ida N, Okura M, Tanaka S, Hosono N, Yamauchi T. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair. Oncology Reports. 2024. doi:10.3892/or.2024.8749
BibTeX
@article{Ida2024,
author = {Ida, Naoko and Okura, Miyuki and Tanaka, Saki and Hosono, Naoko and Yamauchi, Takahiro},
title = {Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair},
journal = {Oncology Reports},
year = {2024},
doi = {10.3892/or.2024.8749}
}
EUVIMED